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were classiﬁed by residential location (urban, suburban, rural).
Massachusetts has 351 cities and towns; 10% urban, 19%
rural, and 71% suburban. Hospital charges, adjusted by a
0.517 cost-to-charge ratio, medical inﬂation and geographic
factors are reported in 2007 US$. RESULTS: The cohort
(n = 53,604) had 92,776 asthma-related encounters (65% ED
visits) during the year. The proportion of ED visits for subur-
ban patients was signiﬁcantly (p < 0.05) lower. On average,
rural patients (2%) had 1.7 encounters (range: 1–11), 5.2
asthma-related care days and accrued $5280 per patient. Sub-
urban patients (46%) averaged 1.6 encounters (range: 1–29),
5.5 care days and $9325 per patient. Urban patients (52%) had
1.8 encounters (range: 1–50), 5.9 care days and $8736 per
patient, on average. Over the year, rural patients used 2768
inpatient days and 1582 ED hours accruing $4.9 million in
asthma-related care costs. Suburban patients accrued 66,823
hospital days, 45,954 ED hours and $116.6 million. Urban
patients used 74,359 hospital days and 46,196 ED hours in one
year, accruing $116.1 million. CONCLUSION: Most patients
were from urban locations; however those from suburban areas
had a higher ratio of inpatient stays to ED visits, which con-
tributed to the higher average asthma-related cost per suburban
patient.
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OBJECTIVES: The objective of this study was to compare costs
and effects of montelukast (MON) as add-on to inhaled corti-
costeroids (ICS) with long-acting â2 agonist (LABA) as add-on
to ICS in adult patients with asthma when compliance is taken
into consideration and from a Swedish health care sector per-
spective. METHODS: A health economic model was developed
to calculate the incremental cost utility ratio of MON com-
pared to the LABA salmeterol (SAL). Head-to-head data from
IMPACT, a two-year 48-week clinical study (N = 1490) of
patients with moderate asthma, was used in the model to esti-
mate the relative effectiveness of the two regimens. The relative
compliance for SAL was assumed to be 0.8 vs 1.0 for MON in
the base case scenario. The analysis included costs for drugs,
asthma events and adverse events. Event rates and asthma spe-
ciﬁc quality of life data for MON and SAL treated patients
were collected from the IMPACT trial, while resource utiliza-
tion and unit costs to treat the events were collected from local
sources. RESULTS: In comparison with SAL, MON is associ-
ated with somewhat higher cost, but has, due to similar efﬁcacy
and better compliance, better effectiveness (more prevented
attacks and more QALYs gain), less asthma-related hospitaliza-
tion, and less serious drug-related side effects. The incremental
cost per QALY for MON + ICS compared to SAL + ICS after
adjusting for relative compliance was 7 000 EUR per QALY in
the base case. CONCLUSION: When added to ICS, MON
compared to SAL shows a favorable cost-utility in Sweden.
This conclusion was stable for reasonable variations in the
modelling assumptions.
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OBJECTIVES: Asthma is a major public health problem with
considerable economic impact. The aim of this study was to asses
the extent of uncontrolled disease and associated medical costs in
severe asthma. METHODS: Data were obtained from the
PHARMO Record Linkage System (PHARMO RLS) which
includes drug dispensing and hospitalizations for 2 million sub-
jects in The Netherlands. Severe asthma patients (12–49 years)
were deﬁned as those who had used long-acting beta-agonists
and inhaled corticosteroids for over 200 days and short-acting
beta agonists for at least 100 days in 2004. Uncontrolled asthma
was deﬁned as a hospitalization for asthma or use of multiple,
short (<30 day) courses of oral corticosteroids. Reimbursed costs
of asthma drugs and hospitalizations were calculated. A matched
case-control analyses was performed to compare asthma treat-
ment of cases (hospitalized for asthma or multiple courses of oral
corticosteroids) and controls. RESULTS: A total of 4.7% of
patients receiving at least 2 asthma preparations in the previous
year had severe asthma. A total of 17.4% of these were deﬁned
as having uncontrolled asthma. Excess drug costs for uncon-
trolled asthma with hospitalization were €664 per patient per
year and €282 per patient per year for patients without hospi-
talization. Including hospital admission costs, excess costs were
over €10,000 per patient per year. Lack of control did not seem
to be caused by under-treatment. CONCLUSION: Poor control
of severe asthma leads to disproportionately increased direct
costs compared to controlled severe asthma, especially when
hospital admission is required. Hospitalized patients representing
2% of the patients with severe asthma are responsible for 23% of
the total direct costs.
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OBJECTIVES: It is estimated that over 4.6 million people suffer
from asthma in England and Wales at an estimated annual cost to
the National Health Service (NHS) of more than 889 million.
Beclometasone dipropionate (BDP) is the current mainstay of
inhaled corticosteroid (ICS) therapy for asthma, and approxi-
mately 80% of patients who are prescribed an ICS receive BDP.
However, chloroﬂuorocarbons (CFC), which are used as propel-
lants in the majority of BDP formulations, are now being phased
out in accordance with the Montreal Protocol, a global initiative
to reduce global warming. QVAR (BDP) utilises environmentally
safe hydroﬂuoroalkane (HFA) in its delivery system. It has
equivalent therapeutic effect at about half the daily dose of CFC
BDP due to superior lung penetration. The UK National Institute
for Health and Clinical Excellence (NICE) are currently apprais-
ing a broad number of ICS licensed for the treatment of chronic
asthma. At the time of the enactment of the Montreal Protocol,
when CFC-based BDP will no longer be manufactured, only HFA
based alternatives will be available. We wished to explore the
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impact of this on the treatment of asthma. METHODS: Our
submission to NICE reviewing the relative value of alternative
products, utilised a cost-minimisation approach, recognising that
there was little evidence of clinical differentiation between the
ICS. RESULTS: It was estimated that a total switch to QVAR
upon withdrawal of CFC based BDP, would result in only a
modest 6% increase in costs to the NHS, but could result in
overall cost savings if it were substituted for more costly ICS
alternatives, such as ﬂuticasone propionate or budesonide. CON-
CLUSION: There remain concerns that NICE may overlook the
current political and socioeconomic imperatives and provide
Guidance that does not consider appropriate BDP dosing or
recognise that the environment will change over its period of
jurisdiction.
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OBJECTIVES: Frequent use of short-acting beta agonists (SABA)
inhalers, along with insufﬁcient use of concurrent steroid inhal-
ers, is often the cause of suboptimal management of the disease.
The aim of the study is to identify the heavy purchasers of SABA
and improve the management of there disease. METHODS: All
Maccabi Healthcare Services (MHS) patients in two areas in the
Shfela district who consumed al least 4 SABA inhalers during
2005 were identiﬁed using MHS’s computerized database. The
patients’ primary care physicians (PCP) were briefed with the
ﬁndings and where presented the current evidence based medi-
cine (EBM) clinical guidelines for proper asthma treatment in a
group meetings with pulmonologist. Later the PCP attend to two
days workshop dealing with appropriate asthma treatment,
patient’s adherence and practicing clinical scenarios with profes-
sional actors. A 3rd meeting included case presentations and
further discussions with a pulomonologist. A control group con-
sisted of patients of PCPs in other areas in the Shfela district
which didn’t participate in the study. RESULTS: One hundred six
patients were in the intervention group. 85 required more then 2
SABA inhalers in the ﬁrst 6 month after intervention (decrease of
20%). In the control group there was a 4% increase in patients
using more than 2 SABA inhalers during the same period (185 to
193). CONCLUSION: We have observed a signiﬁcant improve-
ment in SABA consumption. This improvement applies that edu-
cational efforts on applying EBM clinical guidelines for proper
asthma treatment and providing simple tools for dealing with
patients’ adherence, can improve management and control of
asthma and can lower asthma’s treatment expenses. We suggest
similar interventions on other chronic diseases.
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OBJECTIVES: Clinical efﬁcacy and cost-effectiveness of immu-
notherapy in allergic disease caused by various allergens is dem-
onstrated by several published studies, but economic value is still
far from being appreciated by local decision makers. Scope of
this work was to provide the Regional decision makers with real
world information on the use and impact of immunotherapy in
terms of efﬁcacy on symptoms, use and cost of drugs in patients
affected by rhinoconjunctivitis (RC) with or without asthma (A),
caused by ragweed seasonal allergy. METHODS: Observational
study, of precoseasonal sublingual (SLIT) or preseasonal subcu-
taneous immunotherapy (SCIT) versus non-immunotherapy
(NSIT). Patients enrolled by a network of specialist centres from
Lombardia, were randomly assigned to one of the study groups
and were allowed to take any additional medication needed to
control RC and A symptoms; effectiveness was measured as
global symptom score rated by the patient on a VAS at last visit;
drug consumption was measured as days of medication recorded
by the patient on a weekly diary card during the peak season;
drug cost was calculated by applying Italian NHS prices.
RESULTS: For the ﬁrst year of immunotherapy, 163 adults were
analyzed (SLIT N = 67 M = 48%, age 39+/-9.1; SLIT N = 34
M = 62%, age 41+/-8.1; NSIT N = 62 M = 53%, age 36+/-9.2);
25% of SLIT patients were affected by A as compared to 47% of
SCIT and 37% of NSIT patients; 55% of SLIT patients were
treated with high dose SLIT. The mean number of drug treatment
days/patient was lower for SLIT patients 26.15+/-30.1 vs. NSIT
58.7+/-43.4 (p < 0.0001) and for SCIT patients 33.0+/-45.7 vs
NSIT 58.7+/-43.4 (p < 0.05); similarly the mean total cost/
patient of drug treatment was lower with SLIT €28.19 vs SCIT
€33.9 and NSIT €59.2. CONCLUSION: SLIT and SCIT can
effectively reduce use and cost of drug treatment in adults
affected by rhinoconjunctivitis with/without asthma caused by
ragweed in Lombardia.
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OBJECTIVES: Formoterol/budesonide (BUD/FORM) and sal-
meterol/ﬂuticasone propionate (SAL/FLU) have been shown to
be effective in the treatment of asthma. This retrospective, obser-
vational study compared characteristics of patients initiating
treatment with BUD/FORM or SAL/FLU in routine clinical prac-
tice, subsequent treatment outcomes and resource utilisation.
METHODS: A cohort of German patients diagnosed with
asthma, followed from 12 months before to 12 months after
treatment initiation with BUD/FORM or SAL/FLU, was ex-
tracted from a longitudinal, primary care database of records
collected from June 2000 to June 2006. The primary outcome
was the proportion of successfully treated patients deﬁned
according to utilisation of short-acting beta-agonists (SABA) and
switches or addition of controller medications during the post-
index year. Secondary outcomes included resource utilisation and
acute exacerbations, deﬁned as at least one oral corticosteroid
(OCS) prescription and/or hospitalisation related to asthma.
Regression models were used to adjust for patient characteristics,
including treatment history. RESULTS: The BUD/FORM and
SAL/FLU groups included 1,456 and 982 patients, respectively.
Prior to treatment initiation, patients in the BUD/FORM group
received less asthma-related OCS prescriptions (mean difference:
-0.049, p = 0.0328) but utilisation of SABA, ICS and LABA was
similar. In the year following treatment initiation, patients initi-
ating on BUD/FORM had a greater probability of treatment
success (OR = 1.54, p = 0.0001), fewer acute exacerbations
A402 Abstracts
